EE200100537A - Maduuraftalasiini derivaatide kasutamine proinflammatoorsete tsütokiinide inhibiitoritena - Google Patents

Maduuraftalasiini derivaatide kasutamine proinflammatoorsete tsütokiinide inhibiitoritena

Info

Publication number
EE200100537A
EE200100537A EEP200100537A EEP200100537A EE200100537A EE 200100537 A EE200100537 A EE 200100537A EE P200100537 A EEP200100537 A EE P200100537A EE P200100537 A EEP200100537 A EE P200100537A EE 200100537 A EE200100537 A EE 200100537A
Authority
EE
Estonia
Prior art keywords
pro
inhibitors
inflammatory cytokines
maduraphthalazine
derivatives
Prior art date
Application number
EEP200100537A
Other languages
English (en)
Estonian (et)
Inventor
Draheim Regina
Kronbach Thomas
Heinisch Lothar
Roemer Ernst
H�Fgen Norbert
Poppe Hildegard
J�tten Peter
Haas Wolfgang
Werner Walter
Gr�fe Udo
Original Assignee
Arzneimittelwerk Dresden Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arzneimittelwerk Dresden Gmbh filed Critical Arzneimittelwerk Dresden Gmbh
Publication of EE200100537A publication Critical patent/EE200100537A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200100537A 1999-04-17 2000-04-11 Maduuraftalasiini derivaatide kasutamine proinflammatoorsete tsütokiinide inhibiitoritena EE200100537A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917505A DE19917505A1 (de) 1999-04-17 1999-04-17 Verwendung von Maduraphthalazin-Derivaten als Inhibitoren proinflammatorischer Cytokine
PCT/EP2000/003182 WO2000063181A1 (de) 1999-04-17 2000-04-11 Verwendung von maduraphthalazin-derivaten als inhibitoren proinflammatorischer cytokine

Publications (1)

Publication Number Publication Date
EE200100537A true EE200100537A (et) 2002-12-16

Family

ID=7904992

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100537A EE200100537A (et) 1999-04-17 2000-04-11 Maduuraftalasiini derivaatide kasutamine proinflammatoorsete tsütokiinide inhibiitoritena

Country Status (24)

Country Link
US (1) US6440968B1 (is)
EP (1) EP1171425A1 (is)
JP (1) JP2002542232A (is)
KR (1) KR20010108515A (is)
CN (1) CN1347408A (is)
AU (1) AU4546100A (is)
BG (1) BG106009A (is)
BR (1) BR0009821A (is)
CA (1) CA2305893A1 (is)
CZ (1) CZ20013712A3 (is)
DE (1) DE19917505A1 (is)
EA (1) EA200101096A1 (is)
EE (1) EE200100537A (is)
HK (1) HK1039932A1 (is)
HU (1) HUP0200783A3 (is)
IL (1) IL145600A0 (is)
IS (1) IS6093A (is)
MX (1) MXPA01010050A (is)
NO (1) NO20015033L (is)
SK (1) SK14812001A3 (is)
TR (1) TR200102984T2 (is)
WO (1) WO2000063181A1 (is)
YU (1) YU72601A (is)
ZA (1) ZA200107886B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210535D0 (en) * 2002-05-08 2002-06-19 Novartis Ag Organic compounds
EP2095823A1 (en) * 2002-07-30 2009-09-02 Stem Cell Therapeutics Inc. GM-CSF for treating demyelination
US20070042978A1 (en) * 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
US20080096947A1 (en) * 2004-10-15 2008-04-24 Heidelberg Pharma Ag Parenteral Forms Of Administration Of Imexon And Method For The Production Thereof
EP1908754B1 (en) * 2006-09-19 2009-01-28 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut Antibiotic maduraphthalazin salts with delayed release of the active substance and their use
WO2018011660A1 (en) 2016-07-11 2018-01-18 Philip Morris Products S.A. Hydrophobic capsule
EP3898610B1 (en) * 2018-12-21 2022-10-19 Fondazione Istituto Insubrico di Ricerca per la Vita Novel aza-hexaphene antibiotic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE7706C (de) * Dr. G. H. E. BERING in Bromberg Verfahren zur Entbitterung von Lupinen mit Hülfe kohlensaurer Alkalien
DE19719522A1 (de) * 1996-08-17 1998-02-19 Gruenenthal Gmbh Neue polycyclische Phthalazinderivate, Verfahren zu Ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
YU72601A (sh) 2004-05-12
EA200101096A1 (ru) 2002-04-25
IL145600A0 (en) 2002-06-30
BR0009821A (pt) 2002-01-15
HK1039932A1 (zh) 2002-05-17
JP2002542232A (ja) 2002-12-10
CZ20013712A3 (cs) 2002-03-13
CN1347408A (zh) 2002-05-01
MXPA01010050A (es) 2002-04-24
NO20015033L (no) 2001-11-21
EP1171425A1 (de) 2002-01-16
SK14812001A3 (sk) 2002-05-09
HUP0200783A3 (en) 2002-12-28
DE19917505A1 (de) 2000-10-19
IS6093A (is) 2001-09-28
WO2000063181A1 (de) 2000-10-26
KR20010108515A (ko) 2001-12-07
CA2305893A1 (en) 2000-10-17
US6440968B1 (en) 2002-08-27
TR200102984T2 (tr) 2002-03-21
AU4546100A (en) 2000-11-02
ZA200107886B (en) 2004-03-29
NO20015033D0 (no) 2001-10-16
BG106009A (en) 2002-06-28
HUP0200783A2 (hu) 2002-11-28

Similar Documents

Publication Publication Date Title
AR028567A1 (es) Nuevos derivados de fenil-propargileter
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
EE200300015A (et) Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AR028596A1 (es) Nuevos derivados de fenilglicina
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
NO20021400D0 (no) Terapeutiske konazolinderivater
ATE512949T1 (de) Reninhemmer
ATE363478T1 (de) Renin inhibitoren
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
DK1178986T3 (da) Furanonderivater som inhibitorer af cathepsin S
DE50013404D1 (de) Substituierte 2-dialkylaminoalkylbiphenyl-derivate
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
PT1237857E (pt) Novos derivados fenalquiloxi-fenilo
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
PT1322592E (pt) Derivados substituidos de 1-aminobutan-3-ol
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
EE200100537A (et) Maduuraftalasiini derivaatide kasutamine proinflammatoorsete tsütokiinide inhibiitoritena
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
ATE262517T1 (de) Thiopyranderivate as mmp-inhibitoren
TR200002831A3 (tr) Kinolin-4-Il türevleri I
EE200200389A (et) Imidasooli uued derivaadid
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused